Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Medtronic
Mallinckrodt
McKesson
Johnson and Johnson

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for PTC299


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PTC299?

PTC299 is an investigational drug.

There have been 7 clinical trials for PTC299. The most recent clinical trial was a Phase 1 trial, which was initiated on July 9th 2020.

The most common disease conditions in clinical trials are Nervous System Neoplasms, Pneumonia, and Sarcoma, Kaposi. The leading clinical trial sponsors are PTC Therapeutics, United States Department of Defense, and National Cancer Institute (NCI).

There are nine US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for PTC299
TitleSponsorPhase
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)PTC TherapeuticsPhase 2/Phase 3
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasPTC TherapeuticsPhase 1
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System TumorsNational Cancer Institute (NCI)Phase 1

See all PTC299 clinical trials

Clinical Trial Summary for PTC299

Top disease conditions for PTC299
Top clinical trial sponsors for PTC299

See all PTC299 clinical trials

US Patents for PTC299

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PTC299 ⤷  Try it Free Carboline derivatives useful in the inhibition of angiogenesis PTC Therapeutics, Inc. (South Plainfield, NJ) ⤷  Try it Free
PTC299 ⤷  Try it Free Carboline derivatives useful in the treatment of cancer PTC Therapeutics, Inc. (South Planfield, NJ) ⤷  Try it Free
PTC299 ⤷  Try it Free Administration of carboline derivatives useful in the treatment of cancer and other diseases PTC Therapeutics, Inc. (South Plainfield, NJ) ⤷  Try it Free
PTC299 ⤷  Try it Free Inhibition of VEGF translation PTC Therapeutics, Inc. (South Plainfield, NJ) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PTC299

Drugname Country Document Number Estimated Expiration Related US Patent
PTC299 Austria AT547102 2024-03-15 ⤷  Try it Free
PTC299 Australia AU2005222632 2024-03-15 ⤷  Try it Free
PTC299 Brazil BRPI0508814 2024-03-15 ⤷  Try it Free
PTC299 Canada CA2559408 2024-03-15 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Medtronic
Mallinckrodt
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.